Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Fortis Healthcare Limited — Q1 FY26
Fortis Healthcare delivered a strong Q1 FY26, with consolidated revenue of INR 2,167 crore (+16.6% YoY) and EBITDA of INR 491 crore (+43.2% YoY), driving margin expansion of 420 bps to 22.6%.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Fortis Healthcare delivered a strong Q1 FY26, with consolidated revenue of INR 2,167 crore (+16.6% YoY) and EBITDA of INR 491 crore (+43.2% YoY), driving margin expansion of 420 bps to 22.6%. The hospital business led growth with revenue up 18.6% to INR 1,838 crore, supported by a 10.2% increase in RPOB, improved case mix (oncology +28% YoY, robotic surgeries +75% YoY), and occupancy rising to 69%. Diagnostics revenue grew 7.4% to INR 369 crore, with EBITDA margins surging to 23% from 16.1% YoY. Management guided for 200 bps margin improvement for the full year and expects diagnostics margins to sustain 22-23%. The Gleneagles O&M agreement adds ~700 beds at 3% net revenue fee, providing low-risk EBITDA accretion. Key risks include slower ramp-up of new brownfield beds and potential dilution from integrating underperforming Gleneagles assets.
फोर्टिस हेल्थकेयर ने पहली तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 2,167 करोड़ रुपये रही, जो पिछले साल से 16.6% ज्यादा है। कमाई में से मुनाफा (EBITDA) 491 करोड़ रुपये रहा, जो 43.2% बढ़ा। इससे मुनाफे की दर 22.6% हो गई। अस्पतालों का कारोबार 18.6% बढ़कर 1,838 करोड़ रुपये हुआ। मरीजों की संख्या 10.2% बढ़ी, कैंसर के इलाज में 28% और रोबोटिक सर्जरी में 75% का उछाल आया। डायग्नोस्टिक्स का कारोबार 7.4% बढ़कर 369 करोड़ रुपये हुआ और इसका मुनाफा 16.1% से बढ़कर 23% हो गया। कंपनी को पूरे साल मुनाफे की दर में 2% और सुधार की उम्मीद है। ग्लेनीगल्स समझौते से 700 नए बिस्तर जुड़ेंगे, जिससे कम जोखिम में मुनाफा बढ़ेगा। मुख्य जोखिम नए बिस्तरों का धीमा उपयोग और कमजोर अस्पतालों का एकीकरण है।
Promises0 met · 2 missedRisks3 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
3 risks
Risk Intelligence
Gleneagles O&M assets may underperform expectations
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Occupancy
69%
+2pp YoY
Occupancy improved from 67% in Q1 FY25, driven by higher patient volumes and brownfield expansions.
RPOB (Revenue Per Occupied Bed)
INR 2.65 crore
+10.2% YoY
RPOB growth driven by improved specialty mix, with oncology contributing 16.4% of revenue (up from 15.1%).
Robotic Surgeries Growth
75% YoY
+75% YoY
Robotic surgeries surged 75% YoY, reflecting increased adoption of advanced procedures and higher case complexity.
Diagnostics EBITDA Margin
23%
+690bps YoY
Diagnostics margin expanded sharply from 16.1% in Q1 FY25, driven by operational efficiencies and better product mix.
What Changed vs Last Quarter
NEW
Add ~900 beds in FY26, ~50% operationalized this year
Fortis plans to add approximately 900 beds in FY26, including the recently acquired Shrimann Superspecialty Hospital, with about half becoming operational in the current fiscal.
NEW
Diagnostics revenue growth to reach low double-digits in 6-8 quarters
Agilus expects revenue growth to trend in the high single-digits over the next few quarters, moving to early double-digits in 6-8 quarters.
UPDATED
Hospital EBITDA margin improvement of ~200 bps for FY26
Management reiterated guidance of 200 bps margin expansion for the hospital business in FY26, supported by case mix improvement and operational efficiencies.
UPDATED
Diagnostics EBITDA margin of 22-23% for FY26
Management expects diagnostics EBITDA margins to remain in the 22-23% range for the full year, with Q2 typically stronger.
DROPPED
Hospital revenue growth of 14-15% in FY26
Management expects hospital revenue to grow 14-15% in FY26, with ARPOB growth of 5-6% and volume growth making up the balance.
DROPPED
Agilus double-digit revenue growth and 23% EBITDA margin in FY26
Management targets double-digit revenue growth for Agilus in FY26, with EBITDA margin (net) around 23%, moving towards 25% in a couple of years.
DROPPED
~1,000 bed additions in FY26
Management plans to add approximately 1,000 beds in FY26 through brownfield expansions at Noida, Faridabad, Manesar, FMRI, and BG Road.
NEW RISK
Gleneagles O&M assets may underperform expectations
Analyst raised concern that Gleneagles facilities have historically low margins (~3-4%), and the 3% fee may not capture full upside from operational improvements.
NEW RISK
Diagnostics revenue growth may remain below historical levels
Despite margin improvement, diagnostics revenue growth of 7.4% remains modest; management expects only gradual acceleration to double-digits.
RISK GONE
Legal and legacy costs persist
Legal and other legacy costs continue to consume ~1% of EBITDA, with no near-term resolution expected for the Delhi High Court case.
RISK GONE
Diagnostic revenue growth may lag expectations
Despite margin improvement, Agilus revenue growth has been low single-digit; management's double-digit growth target may be challenged by competitive pressures.
RISK GONE
Geopolitical risks to international patient revenue
International patient revenue growth of 17% may not sustain due to geopolitical tensions, though management expects stable contribution.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q3 FY25
Agilus expects to return to industry-level growth of 8-10% by Q2 FY26, driven by volume growth.
Mentioned in Q2 FY25, Q4 FY25
Management plans to add approximately 1,000 beds in FY26 through brownfield expansions at Noida, Faridabad, Manesar, FMRI, and BG Road.
Mentioned in Q3 FY25, Q4 FY25
Despite margin improvement, Agilus revenue growth has been low single-digit; management's double-digit growth target may be challenged by competitive pressures.
Mentioned in Q1 FY25, Q4 FY25
Legal and other legacy costs continue to consume ~1% of EBITDA, with no near-term resolution expected for the Delhi High Court case.
Fast read
Guidance and risk preview
Management reiterated guidance of 200 bps margin expansion for the hospital business in FY26, supported by case mix improvement and operational eff...
Analyst raised concern that Gleneagles facilities have historically low margins (~3-4%), and the 3% fee may not capture full upside from operationa...
View Risks →